Inversago Pharma

Peripheral cannabinoid (CB1) receptor antagonist/inverse agonist for the treatment of metabolic diseases

placeMontreal, Montreal, Canada calendar_todayFounded 2015 groups25 employees language inversago.com

Registered entities

Innovation

7 patent families — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 41 times.

YearFilings
20212
20222
20236
20243

Investor mix

12 investors on record; lead investors include Forbion, Fonds de solidarite FTQ, Genesys, T1D Fund; 1 has since exited.

Investor typeCountShare
Venture capital867%
Angel & family office18%
Other / undisclosed325%
Coming soon